RCS - GenIP PLC - Commercial Update

GenipAnnouncement

31/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe6857Ya&default-theme=true

RNS Number : 6857Y  GenIP PLC  31 March 2026

 

 

 

31 March 2026

 

GenIP Plc

("GenIP" or the "Company")

 

Commercial Update, Pipeline Development & Strategic Progress

GenIP Plc, the technology evaluation and commercialisation platform, provides
a commercial update on pipeline development, product expansion, and commercial
resourcing as the Company continues to scale rapidly in early 2026, eighteen
months after IPO.

Commercial Highlights:

 

·    Following FY25 revenue growth of c.330%, the Company continues to
receive new orders across the US, Asia and other key markets.

·    Renewal discussions with multiple FY25 clients are progressing well,
with several expanding their scope of work, consistent with GenIP's
historically strong 90% client retention.

·    Asia has become GenIP's largest market, growing c.3,500% year on
year. Europe and Latin America delivered growth of c.111% and c.51%,
respectively.

·    Client demand is shifting toward multi-year, portfolio-level
engagements, increasing engagement size and depth.

·    Invention Prioritizer and Invention Validator continue to gain
traction, broadening the product suite and increasing revenue per client.

·    Commercial leadership strengthened with new enterprise and regional
appointments to support pipeline expansion.

Pipeline Development & Regional Momentum

GenIP's commercial pipeline continues to expand, with multi-institution
opportunities at advanced stages across Asia, Europe, the Middle East and
Latin America. Engagement sizes are increasing as clients seek broader
portfolio-level insights in addition to single-technology evaluations.

Regional growth in FY25 was driven by:

·      Asia: (c.3,500%) - now GenIP's largest market

·      Europe: (c.111%) - accelerating from a low base

·      Latin America: (c.51%) - strong long-term potential supported by
deep institutional connectivity

·      Rest of World: (c.21%)

The breadth of the pipeline provides increasing visibility into multi-year
commercial opportunities.

Product Expansion & Client-Led Development

GenIP's product suite continues to broaden:

Invention Prioritizer - developed in FY25 through work with a leading research
university in Saudi Arabia, is now in active use by multiple clients,
including by CNEN (Brazil's National Nuclear Energy Commission).

Invention Validator - progressing through its first deployment at a leading
South African research university with additional client discussions underway.
The product carries an expected 60% gross margin and complements GenIP's
broader portfolio-support strategy.

Product development remains client-led, ensuring strong market fit and
alignment with evolving customer needs.

Commercial Resourcing

To support the next phase of growth, GenIP has strengthened its commercial
leadership:

Global Enterprise and Corporate Sales Lead - A senior commercial leader has
joined to develop and expand GenIP's previously untapped corporate and
enterprise market on a global scale. This role aligns directly with the
Company's strategy to increase its corporate client base and diversify revenue
beyond its established academic foundation.

Latin America Commercial Lead - A regional specialist with deep institutional
connectivity, including an advisory role with the World Intellectual Property
Organization (WIPO), has been appointed to accelerate regional growth.

Asia Sales Resource - An additional sales resource is being recruited to
support the Company's fastest-growing market.

These appointments enhance GenIP's ability to scale across high growth regions
and support the expanding pipeline.

Outlook and Near-Term Catalysts

GenIP continues to make strong progress against its commercial priorities. The
Company is expanding its global footprint, deepening client relationships and
broadening its product suite.

Near-term commercial catalysts include:

·    Progression of multiple advanced-stage institutional opportunities
across Asia, Europe and Latin America.

·    Expansion of existing FY25 client engagements into multi-year,
portfolio-level programmes.

·    Additional deployments of Invention Prioritizer and Invention
Validator.

·    Strengthening the corporate pipeline under new enterprise sales
leadership.

·    Completion of new commercial hires in Asia to support demand in the
Company's largest market.

 

With rising demand, increasing engagement size and a growing corporate
pipeline, GenIP is well positioned for continued commercial progress in 2026.

Melissa Cruz, Chief Executive Officer, commented:

"GenIP is delivering strong progress across all of our strategic priorities.
Asia's exceptional growth, Europe's accelerating momentum and the long-term
potential we see in Latin America demonstrate the global demand for our
platform and products.

Clients are deepening their engagement with us, adopting our broader product
suite and increasingly seeking portfolio-level insight. With a growing
pipeline, strong renewal activity and a clear strategic focus, GenIP is well
positioned for its next phase of growth."

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                          Via Redchurch Communications

 Melissa Cruz, CEO

 AlbR Capital Limited (Broker)                                      Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                      cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                        Jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                            genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABUGDXLBXDGLG



            Copyright 2019 Regulatory News Service, all rights reserved